STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. - Wikidata - awgldk - TriplyDB

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

http://www.wikidata.org/entity/Q40783216

about

P1343

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells Somatic DNA mutation analysis in targeted therapy of solid tumours Review article: the biology, diagnosis and management of gastrointestinal stromal tumours Hyperplasia of interstitial cells of cajal in sprouty homolog 4 deficient mice Structure of an Unprecedented G-Quadruplex Scaffold in the Human c-kit Promoter A G-Rich Sequence within the c-kit Oncogene Promoter Forms a Parallel G-Quadruplex Having Asymmetric G-Tetrad Dynamics Solution structures of all parallel-stranded monomeric and dimeric G-quadruplex scaffolds of the human c-kit2 promoter KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors From bench to bedside: lessons learned in translating preclinical studies in cancer drug development An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib.Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility Targeted therapy for cancer: the gastrointestinal stromal tumor model.Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line Neurotensin receptor 1 is expressed in gastrointestinal stromal tumors but not in interstitial cells of Cajal.Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability.Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors Targeting G-quadruplexes in gene promoters: a novel anticancer strategy?Gastrointestinal stromal tumors (GIST): a model for molecule-based diagnosis and treatment of solid tumors.Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.Role of human tissue kallikrein in gastrointestinal stromal tumour invasion.All-trans retinoic acid inhibits KIT activity and induces apoptosis in gastrointestinal stromal tumor GIST-T1 cell line by affecting on the expression of survivin and Bax protein.Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase.Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles.Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy Imatinib mesylate, the first molecularly targeted gene suppressor.Oncogenes in melanoma.Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy.Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan.

P2860

Q54835862-847C1915-75B6-4E59-B330-0FE9362218F3

P1343

Q26740953-BED0AFDD-1B67-4792-9111-894DA09AA794 Q26770324-5F749C1E-831E-4148-AC59-C3CC77BE65B1 Q26825310-0BD7F7BB-0514-426E-8C52-71EACB2676CF Q27308910-8C7B2F26-8614-4B73-90D4-902673C419AA Q27644075-D188C499-7432-48E6-B617-0BB603AC1FA7 Q27657150-0192685A-6574-432B-AF47-BEA050EB67FC Q27662546-4DE16830-9CEA-4E6A-98F2-3C8D130D5549 Q27824783-490FB649-9AD5-4131-91B3-BEF8D91A3880 Q27851455-A190D1D4-4D4F-42B6-AA05-E83BF9D40189 Q28483922-644CC03D-5DD3-402F-8C10-BD7DF77F9D9E Q28533949-E3CA340D-5804-47B8-8EA3-C3132C408959 Q33308713-BF383B39-240B-42C0-AFE4-F951716D5164 Q33639728-DCD8D213-F791-49C7-8DC1-82D9A1673045 Q33644791-0D759366-1AE3-416A-965F-C426D5D88957 Q33797591-E8AAB46A-D8B5-4241-A64E-C9DBD423A11C Q33807742-4EA44A38-C87A-4AF5-B9C3-1345BEF19142 Q33825096-1FB5549B-030C-41E7-A96B-608A14C3B979 Q33833577-622235FE-478E-4685-92E9-F274D9B6F04A Q33836021-FC188C1C-B8DB-471A-AB32-A507886FF51F Q33840444-C52EFEC3-E0EB-4806-97A7-5D13BD91FDC3 Q33921067-7581E72F-BEB4-4950-AEB9-79875849B19C Q34050275-851FECD3-E676-4FD7-A80A-A911EB520789 Q34100865-3B4A857F-0061-4C6A-B0BC-AC38BB6B1C9F Q34174883-4FE98A35-D39A-49B2-9A84-0FF8F64265BE Q34208611-E6C034E2-FD09-4D24-807B-684A159E5FE4 Q34289180-341DDFA7-AFC5-4E31-84DF-71E07451C86E Q34344121-F8874C84-6CBE-4558-A01F-9A2B95D4BBEB Q34486028-7C3F6AEE-B031-4259-B3B4-7836A2F0C182 Q34518436-059316B9-56FB-41BF-B7B6-C447851A3D0E Q34533831-D7DEAE06-BFB6-4AB1-94D3-12B28B60AC6A Q34550403-80D03FF2-95E5-4614-9DF6-7B37DFEF7854 Q34597216-E76475D7-44A0-4711-9309-A229CF042857 Q34620856-6D041BF3-CC86-40EE-B70A-A537BD2B6B86 Q34674928-2354E3F9-2F2E-4D29-9616-040D92E18B84 Q34975667-0F0F474F-0019-4FDF-B8A7-A29372EF5DB2 Q35146560-20147131-6700-4737-9F72-A0017A85812F Q35553853-79972B19-1B8B-460D-A43F-189DA36B3F04 Q35586732-9BFFD113-C243-4910-93C4-973F1C311608 Q35607790-FBA8B157-D001-41EA-8BFE-4CC98B91395B Q35626506-C7600092-9A82-4782-A906-CB6926F995C5

P2860

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

http://www.wikidata.org/entity/Q40783216

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

STI571 inactivation of the gas ...... cal and clinical implications.

@en

type

label

STI571 inactivation of the gas ...... cal and clinical implications.

@en

prefLabel

STI571 inactivation of the gas ...... cal and clinical implications.

@en

P1433

Q40783216-8C30425B-21A3-4DAE-8EA3-56F766070419

P1476

Q40783216-5492EEF3-5F3F-4FD6-ACEA-B11BD875EE70

P2093

Q40783216-43813D3E-AE94-4581-AAAE-15D60DA81487

Q40783216-5853E9A0-F092-422A-A76A-FCD82782AFE4

Q40783216-60B681B3-1808-43F8-A495-4CBEE3B81BCC

Q40783216-7563DF83-94F8-4BC0-89AE-66B7544F583E

Q40783216-8146D5F2-2D17-43DD-8A90-293DC2DABA77

Q40783216-8A4F24BB-EA4E-48E4-B825-EF9247C0945D

Q40783216-DD51D791-1B59-435A-B4C2-E7FA9DC495FC

Q40783216-F1203B20-1B0D-4979-A866-42170CC4DA52

P2860

Q40783216-0F101D80-4A23-4BC7-8CBF-2E4AE8BFCC53

Q40783216-14A066B4-4C64-4E10-9F8E-AA91F7A091E3

Q40783216-183A2ABE-B4A1-4287-B16B-3B63FD6F225F

Q40783216-1A325327-2455-49A4-82E8-572A9087B424

Q40783216-61EA8330-00A9-4ED2-BA42-80DC0E242F54

Q40783216-70535226-F213-49B1-A001-3DE88655398D

Q40783216-7147D405-A7DE-48D0-BE57-5A52FF961DA9

Q40783216-777F1D76-558E-4D5D-BD7B-7E6CB7A8A3B5

Q40783216-7E41836E-F4B0-4AEA-9EF5-3A6B477EF92A

Q40783216-7EC3CF56-9BF1-4E59-B3B0-CFB23CA14FC9

P2888

Q40783216-D411E320-17DF-4935-AAB3-D9113BD3FFC0

P304

Q40783216-F1D10501-AFE2-46C7-A59A-F718C5314F10

P31

Q40783216-DADBB201-1863-4805-9A6B-5CF709727CE0

P356

Q40783216-9EB322D2-A099-4D79-9F20-656E5FBD251B

P407

Q40783216-4EEE1188-6D8B-4E86-BFCC-3F44E2A9D868

P433

Q40783216-079A26B1-BD31-4CB1-A3E1-E042E91CF758

P4510

Q40783216-8D7406AF-950F-4E83-841E-7529836DEE92

P478

Q40783216-46340827-8728-4179-B472-40CF44F03293

P577

Q40783216-4852D0AD-A1AF-4B3D-9A34-6AFD0DD93076

P5875

Q40783216-202A1982-969D-4026-A4B1-F24F30FECBF4

P6179

Q40783216-3C0E2385-6E3B-4C8D-9045-1A877995E773

P698

Q40783216-29EFA993-FF24-42FE-8E94-27B77B444DB3

P921

Q40783216-33BA3EF9-0535-431F-A4ED-8254F0A8AF3F

P356

P1433

P1476

STI571 inactivation of the gas ...... cal and clinical implications.

@en

P2093

Demetri GD

http://www.w3.org/2001/XMLSchema#string

Fletcher CD

http://www.w3.org/2001/XMLSchema#string

Fletcher JA

http://www.w3.org/2001/XMLSchema#string

Griffin JD

http://www.w3.org/2001/XMLSchema#string

Jacks T

http://www.w3.org/2001/XMLSchema#string

Singer S

http://www.w3.org/2001/XMLSchema#string

Tuveson DA

http://www.w3.org/2001/XMLSchema#string

Willis NA

http://www.w3.org/2001/XMLSchema#string

P2860

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors.

Gastrointestinal stromal tumors: recent advances in understanding of their biology.

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Characterization of a newly derived human sarcoma cell line (HT-1080).

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases

Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas.

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

P2888

P304

5054-5058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1204704

http://www.w3.org/2001/XMLSchema#string

P407

P433

36

http://www.w3.org/2001/XMLSchema#string

P4510

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11818479

http://www.w3.org/2001/XMLSchema#string

P6179

1036226058

http://www.w3.org/2001/XMLSchema#string

P698

11526490

http://www.w3.org/2001/XMLSchema#string

P921